retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Retatrutide UK | The Ultimate

doi: 10.1080/1028415X.2020.1764292 215

Both therapies produce better outcomes, better dosing accuracy, and better safety profiles when administered in a clinical setting rather than self-managed with online peptides

Supporting NAD through therapy may help restore some of this metabolic capacity

Interested in gut peptides, in 1980 Lund found a gene for the glucagon precursor in Goodman's library (Lund, Goodman, Dee, Habenerr)

It depends on the IV infusion you choose, but it will rehydrate you, energize you, eliminate cramping and soreness, increase mental clarity, stop nausea and vomiting, stop migraines, strengthen your immune system, and make you feel better overall

This helps rebuild cellular energy capacity over time